Focused On-demand Library for RNA-splicing ligase RtcB homolog

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
Q9Y3I0

UPID:
RTCB_HUMAN

ALTERNATIVE NAMES:
3'-phosphate/5'-hydroxy nucleic acid ligase

ALTERNATIVE UPACC:
Q9Y3I0; B2R6A8; Q6IAI0; Q9BWL4; Q9NTH1; Q9P037; Q9P0J3

BACKGROUND:
The RNA-splicing ligase RtcB homolog, alternatively named 3'-phosphate/5'-hydroxy nucleic acid ligase, is integral to RNA biology. It directly joins spliced tRNA halves, forming mature tRNAs by incorporating splice junction phosphate into the tRNA. This enzyme's broad substrate specificity suggests a versatile role in RNA ligase activity, extending possibly beyond tRNA splicing.

THERAPEUTIC SIGNIFICANCE:
Exploring the RNA-splicing ligase RtcB homolog's function offers a promising avenue for developing novel therapeutic strategies. Its indispensable role in RNA processing and splicing mechanisms positions it as a potential target for therapeutic intervention in related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8559 of 8789